NanoViricides Raises $2 Million in Registered Direct Offering to Advance Broad-Spectrum Antiviral Drug
NanoViricides announced a $2 million registered direct offering with a single institutional investor, aiming to fund development of its broad-spectrum antiviral NV-387, which targets multiple viruses including COVID-19, influenza, and RSV.
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage biopharmaceutical company specializing in nanomedicine-based antivirals, has entered into a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds. The offering involves the sale of 1,333,334 common shares or pre-funded warrants, along with accompanying warrants to purchase an equal number of common shares at an exercise price of $1.75 per share, with a three-year term. The closing is anticipated on or about May 18, 2026, subject to customary conditions, as detailed in the press release.
The capital raise comes as NanoViricides advances its lead drug candidate, NV-387, a broad-spectrum antiviral that has shown efficacy in lethal animal models against influenza, respiratory syncytial virus (RSV), coronaviruses, monkeypox, smallpox, and measles. NV-387 has been granted Orphan Drug Designation (ODD) by the U.S. FDA Office of Orphan Products Development, which could provide seven years of market exclusivity upon approval, along with tax credits for clinical trial costs and fee exemptions. The company positions NV-387 as a potential first-line treatment for respiratory viral illnesses, aiming to offer it at a patient's initial doctor visit.
This financing is significant for NanoViricides as it seeks to fund clinical development and manufacturing of NV-387. The company's host-mimetic nanomedicine technology is designed to create antivirals that viruses and their variants cannot easily escape, addressing a critical need in the fight against emerging viral threats. The proceeds from the offering will likely support ongoing trials and regulatory interactions, bringing the drug closer to potential commercialization.
Investors and stakeholders can stay updated on NanoViricides' progress through the company's newsroom. The offering underscores continued investor interest in innovative antiviral therapies, particularly those with broad-spectrum potential that could reduce the impact of future pandemics.